Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOGEN INC.BIIB · Entity 1675 | EVP Pharmaceutical Oper & Tech | January 19, 2022 | January 21, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOGEN INC.
Report date January 19, 2022 · Filed January 21, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,064.131 |
Reported balance
After 2022-01-19 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2022-01-19 · Grant · Acquired 658 · Balance 5,064.131 F1: Represents shares earned upon satisfaction of certain performance conditions associated with performance stock units granted on February 12, 2019. The shares will vest on February 12, 2022. F2: Includes 102.902 shares acquired under the Biogen Inc. employee stock purchase plan on 3/31/2021. |
| Common StockSEC Table I · non-derivative | IndirectBy spouse | 969.366 |
Reported balance
Holding disclosure · report date 2022-01-19 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 969.366 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares earned upon satisfaction of certain performance conditions associated with performance stock units granted on February 12, 2019. The shares will vest on February 12, 2022.
F2: Includes 102.902 shares acquired under the Biogen Inc. employee stock purchase plan on 3/31/2021.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 19, 2022 Filed Jan 21, 2022 21:50 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantCommon Stock | 658 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-001864 · form4.xml · nonDerivative · entry 1 Galdes Alphonse · CIK 0001789471 · EVP Pharmaceutical Oper & Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,064.131 F1 · shares: Represents shares earned upon satisfaction of certain performance conditions associated with performance stock units granted on February 12, 2019. The shares will vest on February 12, 2022. F2 · balance_after: Includes 102.902 shares acquired under the Biogen Inc. employee stock purchase plan on 3/31/2021. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 21:06 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantRestricted Stock Unit · Derivative | 10,870 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-006974 · form4.xml · derivative · entry 1 Galdes Alphonse · CIK 0001789471 · EVP Pharmaceutical Oper & Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,870 Underlying: Common Stock · 10,870 shares Expires 2024-02-18 F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:54 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 1,298 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-006267 · form4.xml · derivative · entry 14 Galdes Alphonse · CIK 0001789471 · EVP Pharmaceutical Oper & Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,522 Underlying: Common Stock · 1,298 shares Expires 2023-02-12 F3 · kind: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:54 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 960 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-006267 · form4.xml · derivative · entry 13 Galdes Alphonse · CIK 0001789471 · EVP Pharmaceutical Oper & Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,820 Underlying: Common Stock · 960 shares Expires 2023-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:54 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 451 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-006267 · form4.xml · derivative · entry 12 Galdes Alphonse · CIK 0001789471 · EVP Pharmaceutical Oper & Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 784 Underlying: Common Stock · 451 shares Expires 2022-02-12 F3 · kind: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:54 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 327 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-006267 · form4.xml · derivative · entry 11 Galdes Alphonse · CIK 0001789471 · EVP Pharmaceutical Oper & Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,235 Underlying: Common Stock · 327 shares Expires 2022-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:54 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 322 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-006267 · form4.xml · derivative · entry 10 Galdes Alphonse · CIK 0001789471 · EVP Pharmaceutical Oper & Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 322 shares Expires 2021-02-12 F3 · kind: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:54 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 286 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-006267 · form4.xml · derivative · entry 9 Galdes Alphonse · CIK 0001789471 · EVP Pharmaceutical Oper & Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 322 Underlying: Common Stock · 286 shares Expires 2021-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:54 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 282 | $278.03 | $78,404.46 |
DisclosureSEC source: 0001127602-21-006267 · form4.xml · nonDerivative · entry 7 Galdes Alphonse · CIK 0001789471 · EVP Pharmaceutical Oper & Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,303.229 Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:54 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 96 | $278.03 | $26,690.88 |
DisclosureSEC source: 0001127602-21-006267 · form4.xml · nonDerivative · entry 6 Galdes Alphonse · CIK 0001789471 · EVP Pharmaceutical Oper & Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,585.229 Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:54 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 84 | $278.03 | $23,354.52 |
DisclosureSEC source: 0001127602-21-006267 · form4.xml · nonDerivative · entry 5 Galdes Alphonse · CIK 0001789471 · EVP Pharmaceutical Oper & Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,681.229 Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:54 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 960 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-006267 · form4.xml · nonDerivative · entry 4 Galdes Alphonse · CIK 0001789471 · EVP Pharmaceutical Oper & Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,765.229 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:54 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 327 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-006267 · form4.xml · nonDerivative · entry 3 Galdes Alphonse · CIK 0001789471 · EVP Pharmaceutical Oper & Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,805.229 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:54 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 286 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-006267 · form4.xml · nonDerivative · entry 2 Galdes Alphonse · CIK 0001789471 · EVP Pharmaceutical Oper & Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,478.229 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:54 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 253 | $278.03 | $70,341.59 |
DisclosureSEC source: 0001127602-21-006267 · form4.xml · nonDerivative · entry 1 Galdes Alphonse · CIK 0001789471 · EVP Pharmaceutical Oper & Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,192.229 F1 · kind: Represents shares withheld to satisfy the withholding tax liability due upon the vesting of shares, as previously disclosed by reporting person on January 29, 2021. Read SEC document |
| January 27, 2021 Filed Jan 29, 2021 21:45 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantCommon Stock | 818 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-002978 · form4.xml · nonDerivative · entry 1 Galdes Alphonse · CIK 0001789471 · EVP Pharmaceutical Oper & Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,445.229 F1 · shares: Represents shares earned upon satisfaction of certain performance conditions associated with performance stock units granted on February 12, 2018. The shares will vest on February 12, 2021. F2 · balance_after: Includes 84.965 shares acquired under the Biogen Inc. employee stock purchase plan on 3/31/2020. Read SEC document |
| February 15, 2020 Filed Feb 19, 2020 23:13 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 333 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-006546 · form4.xml · derivative · entry 5 Galdes Alphonse · CIK 0001789471 · EVP Pharmaceutical Oper & Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 333 shares Expires 2020-02-15 F2 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| February 15, 2020 Filed Feb 19, 2020 23:13 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 441 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-006546 · form4.xml · derivative · entry 4 Galdes Alphonse · CIK 0001789471 · EVP Pharmaceutical Oper & Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 333 Underlying: Common Stock · 441 shares Expires 2020-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| February 15, 2020 Filed Feb 19, 2020 23:13 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 130 | $333.00 | $43,290.00 |
DisclosureSEC source: 0001127602-20-006546 · form4.xml · nonDerivative · entry 2 Galdes Alphonse · CIK 0001789471 · EVP Pharmaceutical Oper & Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,542.264 Read SEC document |
| February 15, 2020 Filed Feb 19, 2020 23:13 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 441 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-006546 · form4.xml · nonDerivative · entry 1 Galdes Alphonse · CIK 0001789471 · EVP Pharmaceutical Oper & Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,672.264 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 23:30 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 420 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-005776 · form4.xml · derivative · entry 13 Galdes Alphonse · CIK 0001789471 · EVP Pharmaceutical Oper & Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,562 Underlying: Common Stock · 420 shares Expires 2022-02-12 F3 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 23:30 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 358 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-005776 · form4.xml · derivative · entry 12 Galdes Alphonse · CIK 0001789471 · EVP Pharmaceutical Oper & Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,982 Underlying: Common Stock · 358 shares Expires 2022-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 23:30 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 294 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-005776 · form4.xml · derivative · entry 11 Galdes Alphonse · CIK 0001789471 · EVP Pharmaceutical Oper & Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 608 Underlying: Common Stock · 294 shares Expires 2021-02-12 F3 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 23:30 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 312 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-005776 · form4.xml · derivative · entry 10 Galdes Alphonse · CIK 0001789471 · EVP Pharmaceutical Oper & Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 902 Underlying: Common Stock · 312 shares Expires 2021-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 23:30 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 484 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-005776 · form4.xml · derivative · entry 9 Galdes Alphonse · CIK 0001789471 · EVP Pharmaceutical Oper & Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 484 shares Expires 2020-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The restricted stock units will vest in 2 annual installments. One-third will vest on the first anniversary of the grant date and two-thirds will vest on the second anniversary of the grant date. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 23:30 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantRestricted Stock Unit · Derivative | 6,780 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-005776 · form4.xml · derivative · entry 8 Galdes Alphonse · CIK 0001789471 · EVP Pharmaceutical Oper & Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,780 Underlying: Common Stock · 6,780 shares Expires 2023-02-12 F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 23:30 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 106 | $331.76 | $35,166.56 |
DisclosureSEC source: 0001127602-20-005776 · form4.xml · nonDerivative · entry 6 Galdes Alphonse · CIK 0001789471 · EVP Pharmaceutical Oper & Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,231.264 Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 23:30 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 358 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-005776 · form4.xml · nonDerivative · entry 5 Galdes Alphonse · CIK 0001789471 · EVP Pharmaceutical Oper & Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,337.264 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 23:30 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 92 | $331.76 | $30,521.92 |
DisclosureSEC source: 0001127602-20-005776 · form4.xml · nonDerivative · entry 4 Galdes Alphonse · CIK 0001789471 · EVP Pharmaceutical Oper & Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,979.264 Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 23:30 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 312 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-005776 · form4.xml · nonDerivative · entry 3 Galdes Alphonse · CIK 0001789471 · EVP Pharmaceutical Oper & Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,071.264 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 23:30 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 153 | $331.76 | $50,759.28 |
DisclosureSEC source: 0001127602-20-005776 · form4.xml · nonDerivative · entry 2 Galdes Alphonse · CIK 0001789471 · EVP Pharmaceutical Oper & Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,759.264 Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 23:30 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 484 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-005776 · form4.xml · nonDerivative · entry 1 Galdes Alphonse · CIK 0001789471 · EVP Pharmaceutical Oper & Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,912.264 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.